Tevard Biosciences Inc, based in Newton Center, MA, is a pioneering biotechnology company focused on developing tRNA-based therapies to treat a wide range of genetic diseases. Founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with parents of children with Dravet syndrome, Tevard aims to revolutionize gene therapy approaches to cure genetic diseases such as Dravet syndrome and others caused by haploinsufficiency and nonsense mutations. With their unique tRNA-based platforms, Tevard is dedicated to providing durable cures for rare diseases by modulating mRNA function and restoring the expression of genes to normal levels appropriate for each type of cell.
With a team of scientific, clinical, and industry leaders, Tevard is committed to bringing their innovative tRNA therapies to patients in a timely manner. Their lead focus is on Dravet syndrome, where they are pursuing a dual approach using Enhancer tRNAs Stabilization and Suppressor tRNAs to increase expression of the healthy copy of SCN1A and allow production of full-length protein off the faulty copy of the gene. Additionally, Tevard is actively developing cures for other genetic epilepsies, CNS indications, and non-CNS indications caused by haploinsufficiency and nonsense mutations, with the aim of addressing the needs of millions of patients worldwide.
Generated from the website